Tacrolimus-related posttransplant lymphoproliferative disorder presenting as autoimmune hemolytic anemia

Archives of Pathology and Laboratory Medicine

Volumn 120, Issue 3, 1996, Pages 282-285

  DiGiuseppe, Joseph A ^a   Bastacky, Sheldon I ^b   Shirey, R Sue ^a   Silberman, Mark A ^a   Hutchins, Grover M ^a   Ness, Paul M ^a,c  

^a DEPARTMENT OF PATHOLOGY   (United States)

^b UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^c JOHNS HOPKINS HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

TACROLIMUS;

ARTICLE; AUTOIMMUNE HEMOLYTIC ANEMIA; CASE REPORT; CHILD; DIFFERENTIAL DIAGNOSIS; GRAFT REJECTION; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; LYMPHOPROLIFERATIVE DISEASE; MALE;

ANEMIA, HEMOLYTIC, AUTOIMMUNE; CHILD; GRAFT REJECTION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LIVER TRANSPLANTATION; LYMPHOPROLIFERATIVE DISORDERS; MALE; POSTOPERATIVE COMPLICATIONS; TACROLIMUS;

EID: 0029866395     PISSN: 00039985     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (25)

1. Starzl TE, Todo S, Fung J, et al. FK 506 for liver, kidney, and pancreas transplantation. Lancet. 1989;2:1000-1004.
2. Todo S, Fung JJ, Tzakis A, et al. One hundred ten consecutive primary orthotopic liver transplants under FK 506 in adults. Transplant Proc. 1991;23: 1397-1402.
3. Fung J, Abu-Elmagd K, Jain A, et al. A randomized trial of primary liver transplantation under immunosuppression with FK 506 vs cyclosporine. Transplant Proc. 1991;23:2977-2983.
4. Fung JJ, Todo S, Tzakis A, et al. Conversion of liver allograft recipients from cyclosporine to FK 506-based immunosuppression: benefits and pitfalls. Transplant Proc. 1991;23:14-21.
5. Demetris AJ, Fung JJ, Todo S, et al. Conversion of liver allograft recipients from cyclosporine to FK506 immunosuppressive therapy: a clinicopathologic study of 96 patients. Transplantation. 1992;53:1056-1062.
6. Craig FE, Gulley ML, Banks PM. Posttransplantation lymphoproliferative disorders. Am J Clin Pathol. 1993;99:265-276.
7. Nalesnik MA, Demetris AJ, Fung JJ, Starzl TE. Lymphoproliferative disorders arising under immunosuppression with FK 506: initial observations in a large transplant population. Transplant Proc. 1991;23:1108-1110.
8. Reyes J, Tzakis A, Green M, et al. Posttransplant lymphoproliferative disorders occurring under primary FK 506 immunosuppression. Transplant Proc. 1991;23:3044-3046.
9. Reding R, Wallemacq PE, Lamy ME, et al. Conversion from cyclosporine to FK506 for salvage of immunocompromised liver allografts in 23 children. Transplantation. 1994;57:93-100.
10. Abu-Elmagd KM, Bronsther O, Kobayashi M, et al. Acute hemolytic anemia in liver and bone marrow transplant patients under FK 506 therapy. Transplant Proc. 1991;23:3190-3192.
11. Walker RH, ed. Technical Manual. Bethesda, Md: American Association of Blood Banks; 1993.
12. Ambinder RF, Mann RB. Epstein-Barr-encoded RNA in situ hybridization: diaonostic applications. Hum Pathol. 1994;25:602-605.
13. Nalesnik MA, Jaffe R, Starzl TE, et al. The pathology of posttransplant lymohoproliferative disorders occurring in the setting of cyclosporine A-prednisone immunosuppression. Am J Pathol. 1988;133:173-192.
14. 0(D) in two Rh-positive patients receiving kidney grafts from an Rh-immunized donor. Transplantation. 1986;41:67-69.
15. Hunt BJ, Yacoub M, Amin S, et al. Induction of red blood cell destruction by graft derived antibodies after minor ABO-mismatched heart and lung transplantation. Transplantation. 1988;46:246-249.
16. Ahmed KY, Nunn G, Brazier DM, et al. Hemolytic anemia resulting from autoantibodies produced by the donor's lymphocytes after renal transplantation. Transplantation. 1987;43:163-164.
17. Rougier JP, Viron B, Ronco P, et al. Autoimmune haemolytic anemia after ABO-match, ABDR full match kidney transplantation. Nephrol Dial Transplant. 1994;9:693-697.
18. Wilkinson LS, Petz LD, Garratty G. Reappraisal of the role of anti-i in haemolytic anemia in infectious mononucleosis. Br J Haematol. 1973;25:715-722.
19. Vaughn JH, Valbracht JR, Nguyen M-D, et al. Epstein-Barr virus-induced autoimmune responses, I: immunoglobulin M autoantibodies to proteins mimicking and not mimicking Epstein-Barr virus nuclear antisen-1. J Clin Invest. 1995;95:1306-1315.
20. Crookston JH. Hemolytic anemia with IgG and IgM autoantibodies and alloantibodies. Arch Intern Med. 1975;135:1314-1315.
21. Freedman J, Newlands M. Autoimmune haemolytic anemia with the unusual combination of both IgM and IgG autoantibodies. Vox Sang. 1977;32:61-68.
22. Sokol RJ, Hewitt S, Stamps BK. Autoimmune haemolysis: mixed warm and cold antibody type. Acta Haematol. 1983;69:266-274.
23. Shulman IA, Branch DR, Nelson JM, et al. Autoimmune hemolytic anemia with both cold and warm autoantibodies. JAMA. 1985;253:1746-1748.
24. McCann EL, Shirey RS, Kickler TS, Ness PM. IgM autoagglutinins in warm autoimmune hemolytic anemia: a poor prognostic feature. Acta Haematol. 1992;88:120-125.
25. Starzl TE, Nalesnik MA, Porter KA, et al. Reversibility of lymphomas and lymphoproliferative lesions developing under cyclosporin-steroid therapy. Lancet. 1984;1:584-587.